{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:09:12Z","timestamp":1762272552885,"version":"build-2065373602"},"reference-count":114,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.neurol.2019.11.010","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T01:21:58Z","timestamp":1588900918000},"page":"710-723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Iatrogenesis and neurological manifestations in the elderly"],"prefix":"10.1016","volume":"176","author":[{"given":"L.","family":"Zerah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Bihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2365-1223","authenticated-orcid":false,"given":"L.-L.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2019.11.010_bib0575","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4904","article-title":"Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study","volume":"339","author":"Collerton","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.neurol.2019.11.010_bib0580","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2307\/3349879","article-title":"Introducing the \u201coldest old.\u201d","volume":"63","author":"Suzman","year":"1985","journal-title":"Milbank Mem Fund Q Health Soc"},{"key":"10.1016\/j.neurol.2019.11.010_bib0585","first-page":"S56","article-title":"The oldest old and the 90+ Study","volume":"4","author":"Kawas","year":"2008","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"10.1016\/j.neurol.2019.11.010_bib0590","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00002512-200926060-00004","article-title":"Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: a prospective survey","volume":"26","author":"Olivier","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neurol.2019.11.010_bib0595","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.arr.2011.03.003","article-title":"Aging with multimorbidity: a systematic review of the literature","volume":"10","author":"Marengoni","year":"2011","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.neurol.2019.11.010_bib0600","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1532-5415.2008.02150.x","article-title":"The co-occurrence of chronic diseases and geriatric syndromes: the health and retirement study","volume":"57","author":"Lee","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.neurol.2019.11.010_bib0605","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2019.11.010_bib0610","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.neurol.2019.11.010_bib0615","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00228-014-1707-9","article-title":"Potentially inappropriate medications and adverse drug reactions in the elderly: a study in a PharmacoVigilance database","volume":"70","author":"Montastruc","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0620","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1474-4422(05)70226-X","article-title":"Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study","volume":"4","author":"Wenning","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0625","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(19)30152-8","article-title":"Recent developments in drug-induced movement disorders: a mixed picture","author":"Factor","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0630","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1001\/archneur.62.2.297","article-title":"Functional correlates and prevalence of mild parkinsonian signs in a community population of older people","volume":"62","author":"Louis","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0635","unstructured":"OHCHR | UPR UPR Mid-term reports n.d. https:\/\/www.ohchr.org\/EN\/HRBodies\/UPR\/Pages\/UPRImplementation.aspx (accessed August 30, 2019)."},{"key":"10.1016\/j.neurol.2019.11.010_bib0640","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.parkreldis.2018.06.030","article-title":"Parkinsonism in a population-based study of individuals aged 75+ years: the Piet\u00e0 study","volume":"56","author":"Vale","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2019.11.010_bib0645","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/mds.26839","article-title":"Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study","volume":"32","author":"Savica","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2019.11.010_bib0650","doi-asserted-by":"crossref","first-page":"442","DOI":"10.5334\/tohm.374","article-title":"Insights into pathophysiology from medication-induced tremor","volume":"7","author":"Morgan","year":"2017","journal-title":"Tremor Hyperkinetic Mov"},{"key":"10.1016\/j.neurol.2019.11.010_bib0655","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S1474-4422(05)70250-7","article-title":"Drug-induced tremors","volume":"4","author":"Morgan","year":"2005","journal-title":"Lancet Neurol"},{"issue":"Suppl. 3","key":"10.1016\/j.neurol.2019.11.010_bib0660","article-title":"Prescribed drugs and neurological complications","volume":"75","author":"Grosset","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2019.11.010_bib0665","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.parkreldis.2013.03.016","article-title":"Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia","volume":"19","author":"Silver","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2019.11.010_bib0670","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","article-title":"Drug-induced parkinsonism: a review of 17 years\u2019 experience in a regional pharmacovigilance center in France","volume":"26","author":"Bondon-Guitton","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2019.11.010_bib0675","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10072-016-2771-y","article-title":"Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype","volume":"38","author":"Munhoz","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2019.11.010_bib0680","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jagp.2015.11.004","article-title":"Lithium use in older adults is associated with increased prescribing of Parkinson medications","volume":"24","author":"Marras","year":"2016","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.neurol.2019.11.010_bib0685","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/jcpt.12162","article-title":"Parkinsonism and severe hypothyroidism in an elderly patient: a case of lithium toxicity due to pharmacological interactions","volume":"39","author":"Basile","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.neurol.2019.11.010_bib0690","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1212\/01.WNL.0000121228.32913.00","article-title":"Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate","volume":"62","author":"Easterford","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2019.11.010_bib0695","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/1060028015594812","article-title":"Extrapyramidal reactions associated with serotonergic antidepressants","volume":"49","author":"Hawthorne","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.neurol.2019.11.010_bib0700","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.21854","article-title":"Failure of recognition of drug-induced parkinsonism in the elderly","volume":"23","author":"Esper","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2019.11.010_bib0705","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12612-012-0264-z","article-title":"Syndromes parkinsoniens et mouvements involontaires m\u00e9dicamenteux dans la population \u00e2g\u00e9e","volume":"4","author":"Bonnet","year":"2012","journal-title":"Cah Ann Gerontol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0710","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/11598540-000000000-00000","article-title":"Drug-induced parkinsonism in the elderly: incidence, management and prevention","volume":"29","author":"L\u00f3pez-Send\u00f3n","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neurol.2019.11.010_bib0715","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/mds.26209","article-title":"Parkinsonism following neuroleptic exposure: a double-hit hypothesis?","volume":"30","author":"Erro","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2019.11.010_bib0720","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.27121","article-title":"Consensus Statement on the classification of tremors. From the task force on tremor of the International Parkinson and Movement Disorder Society","volume":"33","author":"Bhatia","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2019.11.010_bib0725","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00415-016-8357-z","article-title":"The clinical heterogeneity of drug-induced myoclonus: an illustrated review","volume":"264","author":"Janssen","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0730","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00415-003-1010-7","article-title":"Cause and course in a series of patients with sporadic chorea","volume":"250","author":"Piccolo","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0735","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/pn.2007.134585","article-title":"The differential diagnosis of chorea","volume":"7","author":"Wild","year":"2007","journal-title":"Pract Neurol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0740","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.parkreldis.2017.12.032","article-title":"Hyperglycemic chorea\/ballism ascertained over 15 years at a referral medical center","volume":"48","author":"Ryan","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2019.11.010_bib0745","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.archger.2007.05.008","article-title":"Prevalence of movement disorders in an elderly nursing home population","volume":"46","author":"Tse","year":"2008","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.neurol.2019.11.010_bib0750","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JCP.0000000000000344","article-title":"Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database","volume":"35","author":"Abadie","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0755","first-page":"20","article-title":"The Serotonin syndrome: from molecular mechanisms to clinical practice","author":"Francescangeli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurol.2019.11.010_bib0760","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1192\/bjp.bp.107.048371","article-title":"Antidepressant-induced jitteriness\/anxiety syndrome: systematic review","volume":"194","author":"Sinclair","year":"2009","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"10.1016\/j.neurol.2019.11.010_bib0765","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(13)60688-1","article-title":"Delirium in elderly people","volume":"383","author":"Inouye","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2019.11.010_bib0770","doi-asserted-by":"crossref","first-page":"j2047","DOI":"10.1136\/bmj.j2047","article-title":"Hypoactive delirium","volume":"357","author":"Hosker","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.neurol.2019.11.010_bib0775","article-title":"Interventions for preventing delirium in hospitalised non-ICU patients","volume":"3","author":"Siddiqi","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2019.11.010_bib0780","article-title":"Cholinesterase inhibitors for the treatment of delirium in non-ICU settings","volume":"6","author":"Yu","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2019.11.010_bib0785","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(05)67604-0","article-title":"Prevention of falls and consequent injuries in elderly people","volume":"366","author":"Kannus","year":"2005","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2019.11.010_bib0790","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1056\/NEJMcp020719","article-title":"Clinical practice. Preventing falls in elderly persons","volume":"348","author":"Tinetti","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2019.11.010_bib0795","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1532-5415.2011.03386.x","article-title":"Associations between drug burden index and falls in older people in residential aged care","volume":"59","author":"Wilson","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.neurol.2019.11.010_bib0800","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40266-018-00630-z","article-title":"Drugs contributing to anticholinergic burden and risk of fall or fall-related injury among older adults with mild cognitive impairment, dementia and multiple chronic conditions: a retrospective Cohort Study","volume":"36","author":"Green","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neurol.2019.11.010_bib0805","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2217\/pgs-2017-0018","article-title":"the adverse drug reaction of the elderly and the impact of pharmacogenetics","volume":"18","author":"Just","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.neurol.2019.11.010_bib0810","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40266-017-0513-3","article-title":"Associations between the Drug Burden Index. Potentially inappropriate medications and quality of life in residential aged care","volume":"35","author":"Harrison","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neurol.2019.11.010_bib0815","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archinte.167.8.781","article-title":"A drug burden index to define the functional burden of medications in older people","volume":"167","author":"Hilmer","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.neurol.2019.11.010_bib0820","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1017\/S1041610201007487","article-title":"Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents","volume":"13","author":"Arfken","year":"2001","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.neurol.2019.11.010_bib0825","first-page":"371","article-title":"Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics","volume":"19","author":"Seppala","year":"2018","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.neurol.2019.11.010_bib0830","article-title":"Fall-risk-increasing drugs: a systematic review and meta-analysis: III. Others","volume":"19","author":"Seppala","year":"2018","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.neurol.2019.11.010_bib0835","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/bcp.13328","article-title":"Beta-blocker use and fall risk in older individuals: original results from two studies with meta-analysis","volume":"83","author":"Ham","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2017.12.013","article-title":"Fall-risk-increasing drugs: a systematic review and meta-analysis: I. Cardiovascular drugs","volume":"19","author":"de Vries","year":"2018","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.neurol.2019.11.010_bib0845","first-page":"341","article-title":"Moderate potentially drug-induced hyponatremia in older adults: benefit in drug reduction","volume":"68","author":"Peyro Saint Paul","year":"2013","journal-title":"Therapie"},{"key":"10.1016\/j.neurol.2019.11.010_bib0850","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jdiacomp.2017.01.016","article-title":"Glycemic targets in the elderly and the risks of hypoglycemia","volume":"31","author":"Meneilly","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.neurol.2019.11.010_bib0855","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/jdi.12676","article-title":"Continuous glucose monitoring reveals hypoglycemia risk in elderly patients with type 2 diabetes mellitus","volume":"9","author":"Ishikawa","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.neurol.2019.11.010_bib0860","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrendo.2014.170","article-title":"Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications","volume":"10","author":"Frier","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0865","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1475-2840-11-122","article-title":"Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia","volume":"11","author":"Bramlage","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0870","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jdiacomp.2017.02.014","article-title":"Liberating A1C goals in older adults may not protect against the risk of hypoglycemia","volume":"31","author":"Munshi","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.neurol.2019.11.010_bib0875","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1076029616660762","article-title":"Antiplatelet and anticoagulant therapies for prevention of ischemic stroke","volume":"23","author":"Kapil","year":"2017","journal-title":"Clin Appl Thromb"},{"key":"10.1016\/j.neurol.2019.11.010_bib0880","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jama.2017.1371","article-title":"Association of preceding antithrombotic treatment with acute ischemic stroke severity and in-hospital outcomes among patients with atrial fibrillation","volume":"317","author":"Xian","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2019.11.010_bib0885","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/JCP.0000000000000608","article-title":"Antidepressant-associated hyponatremia in the elderly","volume":"36","author":"Greenblatt","year":"2016","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0890","first-page":"139","article-title":"Antidepressant-induced hyponatremia in older adults","volume":"31","author":"Viramontes","year":"2016","journal-title":"Consult Pharm J Am Soc Consult Pharm"},{"key":"10.1016\/j.neurol.2019.11.010_bib0895","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/epi.13593","article-title":"Antiepileptic drugs and hyponatremia in older adults: two population-based cohort studies","volume":"57","author":"Gandhi","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2019.11.010_bib0900","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mus.1171","article-title":"Peripheral neuropathy in young-old and old-old patients","volume":"24","author":"Verghese","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurol.2019.11.010_bib0905","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bcpt.12261","article-title":"Drug-induced peripheral neuropathy","volume":"115","author":"Vilholm","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0910","article-title":"Drug-induced peripheral neuropathy, a narrative review","author":"Jones","year":"2019","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0915","first-page":"413","article-title":"Antiarrhythmic drug-induced side effects: a prospective survey of 300 patients","volume":"50","author":"Vigreux","year":"1995","journal-title":"Therapie"},{"key":"10.1016\/j.neurol.2019.11.010_bib0920","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.22878","article-title":"Neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view","volume":"25","author":"Montastruc","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2019.11.010_bib0925","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.lpm.2007.08.020","article-title":"Drug-related neuropathies: analysis of the French Adverse Drug Reaction Database 1995\u20132005","volume":"37","author":"Durrieu","year":"2008","journal-title":"Presse Med"},{"key":"10.1016\/j.neurol.2019.11.010_bib0930","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/mus.25377","article-title":"Levodopa\/carbidopa intestinal gel therapy for advanced Parkinson disease: an early toxic effect for small nerve fibers?","volume":"54","author":"Devigili","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurol.2019.11.010_bib0935","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0196-0644(89)80933-3","article-title":"Drug- and toxin-induced rhabdomyolysis","volume":"18","author":"Curry","year":"1989","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.neurol.2019.11.010_bib0940","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bcp.12687","article-title":"Myopathy in older people receiving statin therapy: a systematic review and meta-analysis","volume":"80","author":"Iwere","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2019.11.010_bib0945","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.nmd.2010.05.003","article-title":"Myopathies in the elderly: a hospital-based study","volume":"20","author":"Echaniz-Laguna","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.neurol.2019.11.010_bib0950","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40266-018-0590-y","article-title":"Current methods for the treatment and prevention of drug-induced Parkinsonism and tardive dyskinesia in the elderly","volume":"35","author":"Estevez-Fraga","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neurol.2019.11.010_bib0955","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archpsyc.1995.03950210050010","article-title":"Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients","volume":"52","author":"Jeste","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.neurol.2019.11.010_bib0960","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1192\/bjp.171.2.148","article-title":"Incidence and risk factors for severe tardive dyskinesia in older patients","volume":"171","author":"Caligiuri","year":"1997","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"10.1016\/j.neurol.2019.11.010_bib0965","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.neurol.2019.11.010_bib0970","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2019.11.010_bib0975","unstructured":"Antipsychotiques\u00a0: rappel des mesures de suivi cardio-m\u00e9tabolique - Point d\u2019Information - ANSM\u00a0: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 n.d. https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Antipsychotiques-rappel-des-mesures-de-suivi-cardio-metabolique-Point-d-Information\/(language)\/fre-FR (accessed July 17, 2019)."},{"key":"10.1016\/j.neurol.2019.11.010_bib0980","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000318295","article-title":"Do primary care physicians have particular difficulty identifying late-life depression? A meta-analysis stratified by age","volume":"79","author":"Mitchell","year":"2010","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.neurol.2019.11.010_bib0985","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003491.pub2","article-title":"Antidepressants for depressed elderly","author":"Mottram","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2019.11.010_bib0990","first-page":"570","article-title":"Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent: literature review","volume":"8","author":"D\u2019Abreu","year":"2018","journal-title":"Tremor Hyperkinetic Mov N Y N"},{"key":"10.1016\/j.neurol.2019.11.010_bib0995","first-page":"162","article-title":"Medication-induced tardive dyskinesia: a review and update","volume":"17","author":"Cornett","year":"2017","journal-title":"Ochsner J"},{"key":"10.1016\/j.neurol.2019.11.010_bib1000","first-page":"214","article-title":"Benzodiazepine pharmacology and central nervous system-mediated effects","volume":"13","author":"Griffin","year":"2013","journal-title":"Ochsner J"},{"key":"10.1016\/j.neurol.2019.11.010_bib1005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2174\/138920011796504473","article-title":"Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems","volume":"12","author":"Trifir\u00f2","year":"2011","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.neurol.2019.11.010_bib1010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1381612023396654","article-title":"Cognitive and sedative effects of benzodiazepine use","volume":"8","author":"Buffett-Jerrott","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.neurol.2019.11.010_bib1015","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1592\/phco.24.13.1177.38089","article-title":"Paradoxical reactions to benzodiazepines: literature review and treatment options","volume":"24","author":"Mancuso","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neurol.2019.11.010_bib1020","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/bmj.293.6554.1072","article-title":"Confusion after admission to hospital in elderly patients using benzodiazepines","volume":"293","author":"Foy","year":"1986","journal-title":"Br Med J Clin Res Ed"},{"key":"10.1016\/j.neurol.2019.11.010_bib1025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/JGP.0b013e318172b3d0","article-title":"Brain lithium levels and effects on cognition and mood in geriatric bipolar disorder: a lithium-7 magnetic resonance spectroscopy study","volume":"17","author":"Forester","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.neurol.2019.11.010_bib1030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40261-017-0598-9","article-title":"Lithium toxicity in older adults: a systematic review of case reports","volume":"38","author":"Sun","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.neurol.2019.11.010_bib1035","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4088\/JCP.v66n0403","article-title":"Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study","volume":"66","author":"Shulman","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.neurol.2019.11.010_bib1040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40520-015-0359-7","article-title":"Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence","volume":"28","author":"Collamati","year":"2016","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.neurol.2019.11.010_bib1045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/fcp.12450","article-title":"Trends of atropinic (anticholinergic) exposure in the elderly: a 10-year analysis in the French EGB database","volume":"33","author":"Germay","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.neurol.2019.11.010_bib1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2019.02.007","article-title":"Use of anticholinergic drugs according to various criteria and their association with psychological well-being and mortality in long-term care facilities","author":"Aalto","year":"2019","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.neurol.2019.11.010_bib1055","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.neurol.2019.11.010_bib1060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(15)60243-4","article-title":"Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments","volume":"386","author":"Mega","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2019.11.010_bib1065","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(16)30506-2","article-title":"Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study","volume":"388","author":"O\u2019Donnell","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2019.11.010_bib1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.neurol.2019.11.010_bib1075","doi-asserted-by":"crossref","DOI":"10.1177\/2047487319841940","article-title":"Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction","author":"Jortveit","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.neurol.2019.11.010_bib1080","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.neurol.2019.11.010_bib1085","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/S0140-6736(19)30840-2","article-title":"Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial","volume":"393","author":"RESTART Colaboration","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2019.11.010_bib1090","unstructured":"Surveillance of antimicrobial consumption in Europe 2012. Eur Cent Dis Prev Control 2014. http:\/\/ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-consumption-europe-2012 (accessed September 6, 2019)."},{"key":"10.1016\/j.neurol.2019.11.010_bib1095","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.clinthera.2014.09.020","article-title":"Neurotoxicity with antimicrobials in the elderly: a review","volume":"36","author":"Mattappalil","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.neurol.2019.11.010_bib1100","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40264-017-0578-2","article-title":"Neurological adverse effects attributable to \u03b2-lactam antibiotics: a literature review","volume":"40","author":"Deshayes","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.neurol.2019.11.010_bib1105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care Lond Engl"},{"key":"10.1016\/j.neurol.2019.11.010_bib1110","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10096-005-0021-y","article-title":"Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside","volume":"24","author":"Chow","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.neurol.2019.11.010_bib1115","unstructured":"Cancer mortality for common cancers. Cancer Res UK 2015. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/mortality\/common-cancers-compared (accessed August 13, 2019)."},{"key":"10.1016\/j.neurol.2019.11.010_bib1120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.sger.2017.06.010","article-title":"Checkpoint inhibitors, the perspectives for elderly patients","volume":"22","author":"Landre","year":"2017","journal-title":"Soins Gerontol"},{"key":"10.1016\/j.neurol.2019.11.010_bib1125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2018.11.009","article-title":"Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: a literature review","volume":"133","author":"Belgioia","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.neurol.2019.11.010_bib1130","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Advances in cancer immunotherapy","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.neurol.2019.11.010_bib1135","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/17512433.2019.1627200","article-title":"Prescribing issues in elderly individuals living with HIV","volume":"12","author":"Marzolini","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.neurol.2019.11.010_bib1140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.therap.2018.10.006","article-title":"Pharmacoepidemiology in older people: purposes and future directions","volume":"74","author":"Laroche","year":"2019","journal-title":"Therapie"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720304665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720304665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:41:22Z","timestamp":1758519682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378720304665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":114,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0035378720304665"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2019.11.010","relation":{},"ISSN":["0035-3787"],"issn-type":[{"type":"print","value":"0035-3787"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iatrogenesis and neurological manifestations in the elderly","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2019.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}